Paul D. Smith

13.6k citations

120 papers · 7.5k indexed · 3 hit papers · h-index 45

Molecular Biology top 1%
Oncology top 1%
Pulmonary and Respiratory Medicine top 1%
Cancer Research top 1%
Pathology and Forensic Medicine top 1%

Co-authors: Simon J. Cook Matthew J. Sale Elaine Kilgour Wolf Reik A. N. Brooks Christopher J. Caunt Wendy Dean Armelle Logié
Topics: Melanoma and MAPK Pathways (31 papers)Lung Cancer Treatments and Mutations (30 papers)PI3K/AKT/mTOR signaling in cancer (18 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Chemical Reviews Proceedings of the National Academy of Sciences JAMA
Partner nations: United Kingdom United States France

In The Last Decade

Paul D. Smith

117 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

2012 512 citations Paul D. Smith et al. profile →
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

2015 431 citations Paul D. Smith, Simon J. Cook et al. profile →
Challenges and Opportunities in Cancer Drug Resistance

2020 330 citations Paul D. Smith et al. profile →

Peers

Countries citing papers authored by Paul D. Smith

Since Specialization

Citations

This map shows the geographic impact of Paul D. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul D. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul D. Smith more than expected).

Fields of papers citing papers by Paul D. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul D. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul D. Smith. The network helps show where Paul D. Smith may publish in the future.

Co-authorship network of co-authors of Paul D. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Paul D. Smith. A scholar is included among the top collaborators of Paul D. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul D. Smith. Paul D. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance 2022 ·NAR Cancer ·Prasanna Channathodiyil,(unknown),Anne Segonds-Pichon,Paul D. Smith,Simon J. Cook,Jonathan Houseley	3
2	Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer 2019 ·Clinical Cancer Research ·Mariano Ponz‐Sarvisé,Vincenzo Corbo,Hervé Tiriac,Dannielle D. Engle,Kristopher K. Frese,Tobiloba E. Oni,Chang‐Il Hwang,Daniel Öhlund,Iok In Christine Chio,Lindsey A. Baker,Dea Filippini,Kevin Wright,Tashinga E. Bapiro,Pearl S. Huang,Paul D. Smith,Kenneth H. Yu,Duncan I. Jodrell,Youngkyu Park,David A. Tuveson	41
3	MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy 2017 ·Cancer Research ·Mounia Beloueche‐Babari,(unknown),(unknown),Markela Koniordou,Harold G. Parkes,(unknown),Yuen‐Li Chung,Thomas R. Eykyn,Paul D. Smith,Martin O. Leach	105
4	New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome 2017 ·Cancer Research ·(unknown),Adam J. Linley,Dean E. Hammond,Fiona E. Hood,Judy M. Coulson,David J. MacEwan,Sarah J. Ross,Joseph R. Slupsky,Paul D. Smith,Patrick A. Eyers,Ian A. Prior	117
5	Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors 2016 ·Clinical Cancer Research ·Roz Brant,Alan Sharpe,(unknown),Jonathan R. Dry,Elizabeth A. Harrington,J. Carl Barrett,Nicky Whalley,Christopher J. Womack,Paul D. Smith,Darren Hodgson	17
6	Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547 2016 ·Molecular Cancer Therapeutics ·Oona Delpuech,Claire Rooney,Lorraine Mooney,Dawn Baker,Robert A. Shaw,Michael Dymond,Dennis Wang,Pei Zhang,Sarah Cross,Margaret H. Veldman-Jones,Joanne Wilson,Barry R. Davies,Jonathan R. Dry,Elaine Kilgour,Paul D. Smith	18
7	MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model 2015 ·Molecular Cancer Therapeutics ·Chandra Bartholomeusz,Xuemei Xie,(unknown),Kimie Kondo,Ali Dadbin,Jangsoon Lee,Hitomi Saso,Paul D. Smith,Kevin N. Dalby,Naoto T. Ueno	59
8	Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport 2014 ·Molecular Cancer Therapeutics ·Becky M. Bola,Amy L. Chadwick,Filippos Michopoulos,(unknown),Brian A. Telfer,Kaye J. Williams,Paul D. Smith,Susan E. Critchlow,Ian J. Stratford	155
9	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma 2014 ·Cancer Research ·Y.N. Vashisht Gopal,Helen Rizos,Guo Chen,Wanleng Deng,Dennie T. Frederick,Zachary A. Cooper,Richard A. Scolyer,Gulietta M. Pupo,Kakajan Komurov,Vasudha Sehgal,Jiexin Zhang,Lalit R. Patel,Cristiano Gonçalves Pereira,Bradley M. Broom,Gordon B. Mills,Prahlad T. Ram,Paul D. Smith,Jennifer A. Wargo,Georgina V. Long,Michael A. Davies	148
10	Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells 2014 ·Molecular Cancer Therapeutics ·Weiguo Zhang,Vivian Ruvolo,Gao Chen,Liran Zhou,William G. Bornmann,Twee Tsao,Wendy Schober,Paul D. Smith,Sylvie M. Guichard,Marina Konopleva,Michael Andreeff	30
11	Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma 2013 ·Clinical Cancer Research ·Hemant K. Bid,(unknown),Doris A. Phelps,(unknown),Linlin Xiao,Jiayuh Lin,David Capper,(unknown),Brian Geier,Mariko DeWire,Paul D. Smith,Raushan T. Kurmasheva,Xiaokui Mo,Soledad Fernández,Peter J. Houghton	49
12	Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma 2013 ·Clinical Cancer Research ·Marie Cumberbatch,Ximing Tang,Garry Beran,(unknown),Xin Wang,Rebecca Ellston,Simon Dearden,Sabina Cosulich,Paul D. Smith,Carmen Behrens,Edward S. Kim,Xinying Su,Shuqiong Fan,Neil Gray,David P. Blowers,Ignacio I. Wistuba,Chris Womack	22
13	Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer 2013 ·Clinical Cancer Research ·Radosław Polański,Cassandra L. Hodgkinson,Alberto Fusi,Daisuke Nonaka,Lynsey Priest,Paul A. Kelly,Francesca Trapani,Paul Bishop,Anne White,Susan E. Critchlow,Paul D. Smith,Fiona Blackhall,Caroline Dive,Christopher J. Morrow	282
14	Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055) 2012 ·Cancer Research ·Sarah V. Holt,Armelle Logié,Barry R. Davies,Denis Alférez,Sarah Runswick,Sarah E. Fenton,Christine M. Chresta,Yi Gu,Jingchuan Zhang,Yi‐Long Wu,Robert W. Wilkinson,Sylvie M. Guichard,Paul D. Smith	70
15	Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf- Mutant Human Cutaneous Melanoma Cells 2010 ·Cancer Research ·Y.N. Vashisht Gopal,Wanleng Deng,Scott E. Woodman,Kakajan Komurov,Prahlad T. Ram,Paul D. Smith,Michael A. Davies	177
16	The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer 2010 ·Clinical Cancer Research ·Udai Banerji,D. Ross Camidge,Henk M.W. Verheul,Roshan Agarwal,Debashis Sarker,Stan B. Kaye,Ingrid M.E. Desar,Johanna N.H. Timmer-Bonte,Sabine Eckhardt,Karl D. Lewis,Kathryn H. Brown,Mireille Cantarini,Clive Morris,(unknown),Paul D. Smith,Carla M.L. van Herpen	176
17	Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines 2010 ·Molecular Cancer Therapeutics ·Edward B. Garon,Richard S. Finn,Wylie Hosmer,Judy Dering,Charles Ginther,(unknown),Naeimeh Kamranpour,Sharon Pitts,Amrita Desai,David Elashoff,Tim French,Paul D. Smith,Dennis J. Slamon	49
18	The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts 2009 ·Clinical Cancer Research ·Aoife M. Shannon,Brian A. Telfer,Paul D. Smith,(unknown),Armelle Logié,Robert W. Wilkinson,(unknown),Ian J. Stratford,Kaye J. Williams,Stephen R. Wedge	42
19	AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models 2007 ·Molecular Cancer Therapeutics ·Barry R. Davies,Armelle Logié,Jennifer S. McKay,Paul Martin,(unknown),Richard O. Jenkins,Mark Cockerill,(unknown),Paul D. Smith	322
20	Adaptation of nutrient supply to fetal demand in the mouse involves interaction between the Igf2 gene and placental transporter systems 2005 ·Proceedings of the National Academy of Sciences ·Miguel Constância,Emily Angiolini,Ionel Sandovici,Paul D. Smith,(unknown),Gavin Kelsey,Wendy Dean,Anne C. Ferguson‐Smith,Colin P. Sibley,Wolf Reik,Abigail L. Fowden	245

About Paul D. Smith

Paul D. Smith is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 120 papers that have together received 7.5k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (31 papers), Lung Cancer Treatments and Mutations (30 papers) and PI3K/AKT/mTOR signaling in cancer (18 papers). The work is most often cited by research in Cancer Research (1.4k citations), Oncology (2.4k citations) and Molecular Biology (5.1k citations). Paul D. Smith has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Simon J. Cook, Matthew J. Sale, Elaine Kilgour, Wolf Reik, A. N. Brooks, Christopher J. Caunt, Wendy Dean, Armelle Logié, Nicolas Floc’h and Pasi A. Jänne. Their work appears in journals such as Chemical Reviews, Proceedings of the National Academy of Sciences and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact